At a glance
- Originator Pfizer
- Class Antihyperglycaemics
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic complications
Most Recent Events
- 30 Oct 2002 Discontinued - Preclinical for Diabetic complications in USA (unspecified route)
- 22 May 2001 Profile reviewed but no significant changes made
- 10 Apr 1997 No-Development-Reported for Diabetic complications in USA (Unknown route)